Cassava Sciences Inc.
416 Browning Way
South San Francisco
California
94080
United States
Tel: 650-624-8200
Fax: 650-624-8222
Website: http://www.paintrials.com/
278 articles about Cassava Sciences Inc.
-
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer's disease.
-
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
8/3/2022
Cassava Sciences, Inc. today announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam.
-
The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.
-
Cassava Sciences Responds to Media Reports
7/27/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, reiterated today what it had previously disclosed in 2021, that certain government agencies had requested information from the Company.
-
Scientific Community Questions Anti-Amyloid Theory - the Basis for Seminal Alzheimer's Work
7/22/2022
The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with. -
Cassava Sciences is reeling after another journal retracted an article co-authored by a key collaborator on its experimental Alzheimer's disease therapeutic, simufilam.
-
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
5/5/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease.
-
Over the past several years, The Lone Star State has been growing in significance as a life sciences hub. Now the industry is flocking to Hays County and its Innovation Corridor.
-
Cassava Sciences CEO Remi Barbier is hitting back at The New York Times, calling out the newspaper for an article that he claims misrepresented the research of his company.
-
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
4/25/2022
Cassava Sciences, Inc. announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022.
-
Shares of Cassava Sciences plunged after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam.
-
Webcast Details for Cassava Sciences’ Upcoming Fireside Chat
4/4/2022
Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO and Eric Schoen, Chief Financial Officer.
-
Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th
3/30/2022
Cassava Sciences, Inc. announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and presentation on Tuesday, April 5, 2022, at 9am Eastern time.
-
The FDA has not yet issued any hold orders to Cassava, but the company expects that its time is coming after rivals Denali and Cortexyme received theirs.
-
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
2/28/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.
-
Shares of Cassava Sciences are up more than 5% in premarket trading after the FDA denied a Citizen Petition filed last year to suspend the company’s Alzheimer’s clinical trials.
-
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease
12/23/2021
Cassava Sciences, Inc., (NASDAQ: SAVA) a biotechnology company, today announced the launch of a new clinical website, called www.Rethink-ALZ.com. Rethink-ALZ.com is intended to provide access, visibility and information on Cassava Sciences’ Phase 3 safety and efficacy studies of oral simufilam in people with Alzheimer’s disease.
-
Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication
12/21/2021
Cassava Sciences, Inc., a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation in a 2005 paper1 authored by the Company and its scientific collaborators.
-
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
11/18/2021
Cassava Sciences, Inc., a biotechnology company, announced it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease.
-
The U.S. Securities and Exchange Commission has launched an investigation into Texas-based Cassava Sciences.